The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert advising healthcare professionals and patients to monitor adverse reactions of painkiller Meftal, commonly used for menstrual cramps and rheumatoid arthritis.
The mefenamic acid painkiller is prescribed in the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever and dental pain.
The commission, in its alert, stated that a preliminary analysis of adverse drug reactions from the Pharmacovigilance Programme of India (PvPI) database revealed drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome.
"Healthcare professionals, patients/consumers are advised to closely monitor the possibility of the above adverse drug reaction (ADR) associated with the use of the suspected drug," according to the alert, issued on November 30.
If such reaction is encountered, the alert advised, people should report the matter to the national coordination centre of the PvPI under the commission by filing a form on the website - www.ipc.gov.in - or through android mobile app ADR PvPI and PvPI Helpline No. 1800-180-3024.
An autonomous institution of the Ministry of Health, the IPC sets standards for all drugs that are manufactured, sold and consumed in India.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
Video: Ola Cab Driver Suplexed To Ground By Audi Owner For Touching Bumper
US Millionaire, Who Died By Suicide, Owed $34 Million With $8,000 In Bank Elderly Man Slapped, Abused On Train Over Suspicion Of Carrying Beef Manipur Chief Minister Slams Tejashwi Yadav Over "Racist" Jab At Himanta Sarma 8 Killed After Bus Carrying 47 Overturns In US State Of Mississippi: Report Trump "Disrespected Sacred Ground' At US Military Cemetery: Kamala Harris Top 10 US Universities Based On Forbes Rankings 2024 Track Latest News Live on NDTV.com and get news updates from India and around the world.